The use of berberine for women with polycystic ovary syndrome undergoing <scp>IVF</scp> treatment

An, Yuan; Sun, Zilin; Zhang, Yajuan; Liu, Bin; Guan, Yu; Lu, Meisong

doi:10.1111/cen.12294

Cited by 77 publications

(124 citation statements)

References 24 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…There was moderate‐quality evidence, from 13 studies involving 1551 women, that showed no significant difference in using antagonist or agonist protocols for ovarian stimulation (RR = 1.02 (95% CI, 0.91–1.15), I 2 = 7%). Low‐quality evidence, from 12 studies involving 1004 women, further suggested that the administration of metformin has a positive effect on clinical pregnancy compared with placebo or no metformin (RR = 1.26 (95% CI, 1.04–1.53), I 2 = 24%). Low‐quality evidence further suggested that there was no clinical difference between ovulation induction and estradiol for endometrial preparation for FET.…”

Section: Resultsmentioning

confidence: 99%

Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta‐analysis

Kollmann

Martins

Lima

et al. 2016

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta‐analysis

Kollmann

Martins

Lima

et al. 2016

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

“…Berberine is an effective insulin sensitizer and has comparable property to metformin (An et al, ). Berberine has been used to recover insulin resistance and to improve ovulation induction in patients with PCOS (Wu et al, ).…”

Section: Endocrinementioning

confidence: 99%

“…Three months of treatment with metformin or berberine before the IVF cycle reduced the incidence of severe ovarian hyperstimulation syndrome and enhanced the pregnancy rate. In addition, treatment with berberine, in comparison with metformin, was associated with fewer gastrointestinal adverse effects and in the reduction of lipid parameters, BMI, and total FSH requirement (An et al, ).…”

Section: Endocrinementioning

confidence: 99%

Berberine and barberry (Berberis vulgaris): A clinical review

Imenshahidi

Hosseinzadeh

2019

Phytotherapy Research

222

109

View full text Add to dashboard Cite

Barberry (Berberis vulgaris L.) has different medicinal applications in folk medicine of Iran. Berberine, an alkaloid constituent of this plant, is present in the roots, rhizomes, stem, and bark of B. vulgaris and many other plants. There have been many clinical trials conducted that suggested a wide range of therapeutic applications. Here, we investigated the clinical uses of berberine and B. vulgaris in the treatment of different diseases in humans. An extensive search in electronic databases (PubMed, Scopus, Embase, Web of Sciences and Science Direct) was used to identify the clinical trials on B. vulgaris and berberine. Lipid‐lowering and insulin‐resistance improving actions are the most studied properties of berberine in numerous randomized clinical trials. There are also clinical trials regarding cardiovascular, anticancer, gastrointestinal, CNS, endocrine, and so on. Berberine has very low toxicity in usual doses and reveals clinical benefits without major side effects. Only mild gastrointestinal reactions may occur in some patients. The purpose of this review is to provide a summary concerning the clinical trials conducted on berberine to improve the clinical application of this nutraceutical in different diseases. In this review article, we used 77 clinical studies on human subjects.

show abstract

“…One potential prophylactic candidate, berberine (BBR), merits further exploration as it has already proved to be of importance for a variety of diseases through successful clinical trials, such as polycystic ovary syndrome [30,31], type II diabetes [32,33], diarrhea-predominant irritable bowel syndrome [34], psoriasis [35], and osteoarthritis [36]. Additionally, current clinical trials are assessing BBR's ability to help ulcerative colitis (UC) patients maintain remission (NCT No.02962245), to prevent colorectal cancer development in UC patients who are in remission (NCT No.…”

Section: Berberinementioning

confidence: 99%

“…Side effects reported after oral administration are considered to be mild (e.g. diarrhea, flatulence, abdominal pain, nausea, and constipation), and do not occur in all patients [30,32,38,39]; there were no adverse effects observed on liver and kidney function [32,33,40]. Notably, amelioration of side effects in patients has been reported once dosage was lowered [33].…”

Section: Berberinementioning

confidence: 99%

Berberine delays onset of collagen induced arthritis through T cell suppression

Vita¹,

Lyons²,

Aljobaily³

et al. 2019

Preprint

View full text Add to dashboard Cite

RUNNING TITLE (less than 50 characters): Berberine delays onset of collagen arthritis model KEY WORDS (5 words not in the title): CIA, berberine, RA, autoimmune, T cell ABSTRACT (250 words or less): Previous evidence suggests that berberine (BBR), a clinically relevant plant-derived alkaloid, alleviates symptoms of clinically apparent collagen induced arthritis (CIA), and may have a prophylactic role from in vitro studies. Thus, we used a CIA model to determine if BBR merits further exploration as a prophylactic treatment for rheumatoid arthritis. Mice were treated with either 1 mg/kg/day of BBR or a vehicle (PBS) control via IP injections from day 0 to day 28, were left untreated (CIA control), or were in a non-arthritic control group. Incidence of arthritis in BBR mice was 40%, compared to 90% in the CIA and 80% in the PBS controls. Populations of B cells and T cells from the spleens and draining lymph nodes were examined from mice across treatment groups on day 14 and from the remaining mice on day 28 when arthritic signs and symptoms were expected to be apparent. BBR-treated mice had significantly reduced populations of CD4 + T cells, CXCR5 + T fh cells, and an increased proportion of T reg at both day 14 and day 28 endpoints, as well as decreased CD28 + and CD154 + CD4 + T cells at day 14. BBR-treated mice also experienced a significant reduction of CD19 + B cells in LNs at day 28. Additionally, BBR treatment resulted in significantly lower anti-collagen type II-specific (anti-CII) IgG2a and anti-CII total IgG serum concentrations. These results indicate a potential role for BBR as a prophylactic supplement, and that its effect may be mediated through T cell suppression, which indirectly affects B cell activity. and PBS controls ( Fig. 2B). When comparing anti-CII IgG levels between arthritic and nonarthritic mice within the BBR group specifically, however, anti-CI IgG1, IgG2a and total IgG were all significantly reduced in the non-arthritic mice compared to those who developed arthritis (Fig. 2C). Additionally, there appeared to be a vehicle-specific effect on circulating anti-CII IgG in which the administration of PBS with 0.01% DMSO elicited elevated levels of anti-CII IgG1 and total IgG in vehicle control mice ( Fig. 2A-B).Key CD4 + T cell population characteristics in response to berberine treatment-On day 14, we observed a significant reduction in populations of both CD4 + T cells and CXCR5 + T fh cells in the LNs and spleen of BBR-treated mice (Fig. 3A-B), as well as a reduction in the percentage of CD28 + and CD154 + CD4 + T cells in the spleen and LNs of BBR-treated mice (Fig. 3A-B). By the day 28 experimental endpoint we continued to observe a significant reduction in CD4 + T cells and CXCR5 + T fh cells in the spleen and LNs of BBR-treated mice ( Fig. 3C-D), however, there was no significant difference in the percentage of CD28 + and CD154 + CD4 + T cells between treatment groups (Fig 3C-D). Berberine treatment leads to increased proportion of FOXP3 + CD25 + CD4 + T cells-To examineBBRs effect on ...

show abstract

The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment

Abstract: Berberine and metformin treatments prior to IVF improved the pregnancy outcome by normalizing the clinical, endocrine and metabolic parameters in PCOS women. Berberine has a more pronounced therapeutic effect and achieved more live births with fewer side effects than metformin.

Cited by 77 publications

References 24 publications

Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta‐analysis

Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta‐analysis

Berberine and barberry (Berberis vulgaris): A clinical review

Berberine delays onset of collagen induced arthritis through T cell suppression

Contact Info

Product

Resources

About